4-溴-2-乙酰基噻吩 | 7209-11-2

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-溴-2-乙酰基噻吩
• 中文别名: 1-(4-溴-2-噻吩)乙酮；2-乙酰基-4-溴噻吩；1-(4-溴-2-噻吩基)乙酮
• 英文名称: 2-acetyl-4-bromothiopene
• 英文别名: 1-(4-bromothiophen-2-yl)ethan-1-one；1-(4-bromothiophen-2-yl)ethanone；1-(4-bromo-2-thienyl)ethanone；2-acetyl-4-bromothiophene；1-(4-bromo-thien-2-yl)ethanone
• CAS: 7209-11-2
• 化学式: C₆H₅BrOS
• mdl: MFCD01566552
• 分子量: 205.075
• InChiKey: HXVLWNKFMNRJED-UHFFFAOYSA-N

物化性质

• 沸点：
  66-67°C 0,2mm
• 密度：
  1.619±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  室温且干燥

SDS

Name:	1-(4-Bromo-2-thienyl)ethan-1-one tech Material Safety Data Sheet
Synonym:	2-Acetyl-4-bromothiophen
CAS:	7209-11-2

Section 1 - Chemical Product MSDS Name:1-(4-Bromo-2-thienyl)ethan-1-one tech Material Safety Data Sheet
Synonym:2-Acetyl-4-bromothiophen

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
7209-11-2	1-(4-Bromo-2-thienyl)ethan-1-one		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7209-11-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5BrOS
Molecular Weight: 205

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7209-11-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Bromo-2-thienyl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 7209-11-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 7209-11-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7209-11-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用 1-(4-溴-2-噻吩)乙酮可用作有机合成中间体和医药中间体，主要用于实验室研发过程和化工生产过程中。

制备 在装有温度计和回流冷凝管的2L三口瓶中，依次加入2-溴噻吩、冰醋酸，并在机械搅拌下逐滴加入醋酸酐。随后升温至回流状态并维持3小时，直至反应完全。将反应液中的冰醋酸以及过量的乙酸酐旋干后，所得灰白色固体再加入甲苯中打浆处理，过滤并用真空烘箱干燥，最终得到2-乙酰基-4-溴噻吩。

反应信息

• 作为反应物：
  描述：

  4-溴-2-乙酰基噻吩 在 钯 sodium tetrahydroborate 、 氢气 、 calcium oxide 作用下， 以 乙醇 为溶剂， 生成 2-乙酰基噻吩
  参考文献：
  名称：

  催化还原脱溴—一种制备氘代噻吩和呋喃的新方法

  摘要：

  DOI：

  10.1007/bf00512954
• 作为产物：
  描述：

  2-乙酰基噻吩 在 溴 作用下， 以 氯仿 为溶剂， 以43%的产率得到4-溴-2-乙酰基噻吩
  参考文献：
  名称：

  基于吡咯的S-亚硝基谷胱甘肽还原酶抑制剂的构效关系：羧酰胺修饰

  摘要：

  酶S-亚硝基谷胱甘肽还原酶（GSNOR）是调节水平的乙醇脱氢酶家族（ADH）的成员S-通过亚硝基硫醇分解代谢（SNOS）S-亚硝基谷胱甘肽（GSNO）。GSNO和SNO与许多疾病的发病机制有关，包括呼吸系统，胃肠道和心血管系统的疾病。基于吡咯的N6022最近被鉴定为有效，选择性，可逆和有效的GSNOR抑制剂，目前正用于急性哮喘的临床开发中。我们在这里描述了N6022的新型基于吡咯的类似物的合成及其结构-活性关系（SAR），其重点是在侧链N上的羧酰胺修饰。-苯基部分。我们已经确定了有效和新颖的GSNOR抑制剂，它们在卵白蛋白（OVA）诱发的哮喘小鼠模型中显示出功效。

  DOI：

  10.1016/j.bmcl.2012.01.047

文献信息

• TETRAHYDROPYRROLOTHIAZINE COMPOUNDS
  申请人：ELI LILLY AND COMPANY

  公开号：US20130261111A1

  公开（公告）日：2013-10-03

  The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R 1 is H or F; R 2 is H, —CH 2 OH, C 1 -C 3 alkyl, R 3 is H, F, or CN; R 4 is H, F; or CN; and R 5 is H, —CH 3 , or —OCH 3 ; or a pharmaceutically acceptable salt thereof.

  本发明提供了以下式I的化合物： 其中A选自以下组合之一； R1为H或F； R2为H，—CH2OH，C1-C3烷基， R3为H，F或CN； R4为H，F；或CN；和 R5为H，—CH3，或—OCH3； 或其药学上可接受的盐。
• Palladium-Catalyzed Cross-Coupling Reaction of Tricyclopropylbismuth with Aryl Halides and Triflates
  作者：Alexandre Gagnon、Martin Duplessis、Pamela Alsabeh、Francis Barabé

  DOI：10.1021/jo702377h

  日期：2008.5.1

  The palladium-catalyzed cross-coupling reaction of tricyclopropylbismuth with aryl and heterocyclic halides and triflates is reported. The reaction tolerates numerous functional groups and does not require anhydrous conditions. The method was successfully extended to the cross-coupling of triethylbismuth.

  报道了钯催化的三环丙基铋与芳基和杂环卤化物以及三氟甲磺酸酯的交叉偶联反应。该反应可耐受许多官能团，并且不需要无水条件。该方法已成功地扩展到三乙基铋的交叉偶联。
• HETEROCYCLIC INHIBITORS OF MCT4
  申请人：Vettore, LLC

  公开号：US20180162822A1

  公开（公告）日：2018-06-14

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。
• [EN] MCT4 INHIBITORS FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE MCT4 POUR LE TRAITEMENT DE MALADIES
  申请人：VETTORE LLC

  公开号：WO2016201426A1

  公开（公告）日：2016-12-15

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一种在治疗MCT4介导的疾病中有用的化合物和组合物，如增殖性和炎症性疾病，其具有Formula I的结构：还提供了在人类或动物主体中抑制MCT4活性的方法。
• A new and convenient synthetic way to 2-substituted thieno[2,3-<i>b</i>]indoles
  作者：Roman A Irgashev、Arseny A Karmatsky、Gennady L Rusinov、Valery N Charushin

  DOI：10.3762/bjoc.11.112

  日期：——

  A short and robust approach for the synthesis of 2-(hetero)aryl substituted thieno[2,3-b]indoles from easily available 1-alkylisatins and acetylated (hetero)arenes has been advanced. The two-step procedure includes the “aldol-crotonic” type of condensation of the starting materials, followed by treatment of the intermediate 3-(2-oxo-2-(hetero)arylethylidene)indolin-2-ones with Lawesson’s reagent. The latter process involves two sequential reactions, namely reduction of the C=C ethylidene double bond of the intermediate indolin-2-ones followed by the Paal–Knorr cyclization, thus affording tricyclic thieno[2,3-b]indoles.

  一种简洁而强大的方法用于从易得的1-烷基异色酮和乙酰化的(杂)芳烃合成2-(杂)芳基取代的噻吩[2,3-b]吲哚。这种两步法包括起始原料的“醛-巴豆酸”类型的缩合反应，随后处理中间体3-(2-氧代-2-(杂)芳基乙烯基亚甲基)吲哚-2-酮与劳森试剂。后者的过程涉及两个连续反应，即还原中间体吲哚-2-酮的C=C乙烯双键，然后进行Paal-Knorr环化反应，从而得到三环噻吩[2,3-b]吲哚。